Compare CTBI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTBI | ERAS |
|---|---|---|
| Founded | 1903 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | CTBI | ERAS |
|---|---|---|
| Price | $56.45 | $3.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $59.00 | $3.71 |
| AVG Volume (30 Days) | 66.4K | ★ 2.7M |
| Earning Date | 01-16-2026 | 11-12-2025 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | ★ 17.49 | N/A |
| EPS | ★ 5.17 | N/A |
| Revenue | ★ $261,447,000.00 | N/A |
| Revenue This Year | $21.01 | N/A |
| Revenue Next Year | $6.33 | N/A |
| P/E Ratio | $10.93 | ★ N/A |
| Revenue Growth | ★ 13.97 | N/A |
| 52 Week Low | $44.60 | $1.01 |
| 52 Week High | $61.55 | $3.80 |
| Indicator | CTBI | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 59.59 |
| Support Level | $59.58 | $3.39 |
| Resistance Level | $58.69 | $3.77 |
| Average True Range (ATR) | 1.26 | 0.25 |
| MACD | -0.55 | -0.02 |
| Stochastic Oscillator | 3.91 | 57.29 |
Community Trust Bancorp Inc is a bank holding company. The Bank owns all the capital stock of one commercial bank and one trust company, serving small and mid-sized communities in eastern, north-eastern, central, and southcentral Kentucky, southern West Virginia, and north-eastern Tennessee. Through its subsidiaries, the Bank is engaged in commercial and personal banking and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals, and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes; and providing funds transfer services.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.